Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade
| العنوان: | Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade |
|---|---|
| المؤلفون: | Suhasini Iyer, Sherry Yeh, Kathy Howell, Mercedesz Balazs, Laura DeForge, Jeffrey Thompson, Allen J. Ebens, Zhonghua Lin, Christine Ambrose, Maya Leabman, Germaine Fuh, Shiming Ye, Wyne P. Lee, Qinglin Ou, Thomas Gelzleichter, Chingwei V. Lee, Wei Yu Lin, Dimitry M. Danilenko, Melissa A. Starovasnik, Joseph Beyer, Qian Gong, Dhaya Seshasayee, Flavius Martin, Jean Shu, Eric Suto |
| المصدر: | Blood. 110:3959-3967 |
| بيانات النشر: | American Society of Hematology, 2007. |
| سنة النشر: | 2007 |
| مصطلحات موضوعية: | Cell Survival, medicine.drug_class, medicine.medical_treatment, Plasma Cells, Immunology, Bone Marrow Cells, Monoclonal antibody, Biochemistry, Lymphocyte Depletion, Mice, Species Specificity, Antigen, Neoplasms, B-Cell Activating Factor, Animals, Medicine, B-cell activating factor, B cell, CD20, Mice, Inbred BALB C, biology, business.industry, Antibodies, Monoclonal, Cell Biology, Hematology, Immunotherapy, Blockade, Macaca fascicularis, medicine.anatomical_structure, Immune System Diseases, biology.protein, Antibody, business, B-Cell Activation Factor Receptor |
| الوصف: | Removal of pathogenic B lymphocytes by depletion of monoclonal antibodies (mAbs) or deprivation of B-cell survival factors has demonstrated clinical benefit in both oncologic and immunologic diseases. Partial clinical responses and emerging data demonstrating incomplete B-cell depletion after immunotherapy fuels the need for improved therapeutic modalities. Lessons from the first generation of therapeutics directed against B-cell-specific antigens (CD20, CD22) are being applied to develop novel antibodies with additional functional attributes. We describe the generation of a novel class of B-cell-directed therapy (anti-BR3 mAbs) that combines the depleting capacity of a therapeutic mAb and blockade of B-cell-activating factor (BAFF)–BR3 B-cell survival. In mice, treatment with antagonistic anti-BR3 antibodies results in quantitatively greater reduction in some B-cell subsets and qualitatively different effects on bone marrow plasma cells compared with BR3-Fc BAFF blockade or with anti-CD20 treatment. Comparative analysis of BR3-Fc and anti-BR3 mAb reveals a lower B-cell dependence for BAFF-mediated survival in nonhuman primates than in mice. This novel class of B-cell-targeted therapies shows species characteristics in mice and primates that will guide translation to treatment of human disease. |
| تدمد: | 1528-0020 0006-4971 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::097d141204a369c61e0bbe2e44212d6aTest https://doi.org/10.1182/blood-2007-04-088088Test |
| رقم الانضمام: | edsair.doi.dedup.....097d141204a369c61e0bbe2e44212d6a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15280020 00064971 |
|---|